Theraclion: 2015 Financial Agenda

Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specializing in cutting-edge medical equipment for echotherapy, today announced its financial agenda for 2015.

Financial publications will be released before market opening. This schedule is indicative and subject to change.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on cutting-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 23 people, 65 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
Eligible for the PEA-PME, a tax-exempt share savings plan for SMEs
Ticker symbol: ALTHE – ISIN code: FR0010120402